Bavarian Nordic A/S (VIE:BAVA)
Austria · Delayed Price · Currency is EUR | Market Cap | 2.22B -10.1% |
| Revenue (ttm) | 847.76M -1.8% |
| Net Income | 206.34M +8.4% |
| EPS | 2.60 +8.1% |
| Shares Out | n/a |
| PE Ratio | 10.76 |
| Forward PE | 18.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 29.50 |
| Previous Close | 29.16 |
| Day's Range | 29.50 - 29.70 |
| 52-Week Range | 22.96 - 32.47 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 21, 2026 |
About Bavarian Nordic
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses... [Read more]
Financial Performance
In 2025, Bavarian Nordic's revenue was 6.24 billion, an increase of 9.23% compared to the previous year's 5.72 billion. Earnings were 1.38 billion, an increase of 39.21%.
Financial numbers in DKK Financial StatementsNews
Bavarian Nordic Launches First DKK 250 Mln Tranche Of Share Buyback Program
(RTTNews) - Bavarian Nordic A/S (BAVA.CO, BVNKF), a vaccine company, on Tuesday launched the first tranche of the share buyback program announced on August 21, under which the company intends to repur...
Bavarian Nordic Earnings Call Transcript: Q2 2026
H1 2026 revenue exceeded DKK 3 billion with 35% EBITDA margin, driven by strong Travel Health and Public Preparedness growth. Full-year guidance was upgraded to DKK 5.7 billion revenue and 30% EBITDA margin, with a new DKK 750 million share buyback announced.
Bavarian Nordic Quarterly report: Q2 2026
Bavarian Nordic has published its Q2 2026 quarterly earnings report on August 21, 2026.
Bavarian Nordic Slides: Q2 2026
Bavarian Nordic has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 21, 2026.
Global warming widens spread of TBE, chikungunya, Bavarian Nordic boss says
Global warming is increasing the spread of tick-borne encephalitis and chikungunya viruses, the chief executive of vaccine maker Bavarian Nordic said on Friday.
Bavarian Nordic Posts Strong First Half, Travel Health Drives Growth; Stock Up
(RTTNews) - Bavarian Nordic A/S (BAVA) reported solid earnings and revenue growth for the second quarter and first half of 2026, supported by strong vaccine sales and upgraded full-year guidance.
Bavarian Nordic Q2 Revenue Up 23%, Upgrades 2026 Guidance; To Initiate Share Buy-back
(RTTNews) - Bavarian Nordic A/S (BAVA.CO) reported that its second quarter EBITDA was 925 million Danish kroner, corresponding to an EBITDA margin of 45%. Revenue in the second quarter increased by 23...
Bavarian Nordic's IMVANEX Wins EU Approval For Expanded Pediatric Use Against Mpox And Smallpox
(RTTNews) - Bavarian Nordic A/S (BVNKF, BAVA.CO), a vaccine company, on Friday announced that the European Commission has approved a Type 2 variation for IMVANEX, extending the smallpox and mpox vacci...
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
COPENHAGEN, Denmark, June 29, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on June 2, 2026, under which the Company will repurchase shares fo...
Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine
COPENHAGEN, Denmark, June 29, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Health Canada has approved VIMKUNYA® (recombinant, adsorbed) for immunization to prevent disease caused by chi...
Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine
COPENHAGEN, Denmark, June 9, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a government contract valued over DKK 700 million to supply its MVA-BN® smallpox/mpox vaccine to an und...
Bavarian Nordic Launches Next Tranche of Share Buy-Back Program
COPENHAGEN, Denmark, June 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the third and final tranche of the planned buy-back program, under which the Company intends to repurchase own shares...
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
COPENHAGEN, Denmark, May 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding manage...
Bavarian Nordic Earnings Call Transcript: Q1 2026
Q1 2026 saw revenue of DKK 1,058 million and a 16% EBITDA margin, with strong travel health growth and upgraded full-year guidance following a new BARDA contract. Travel health and public preparedness segments both contributed, and cash position remains robust.
Bavarian Nordic Quarterly report: Q1 2026
Bavarian Nordic has published its Q1 2026 quarterly earnings report on May 13, 2026.
Bavarian Nordic Slides: Q1 2026
Bavarian Nordic has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Bavarian Nordic Announces Interim Results for the First Three Months of 2026
COPENHAGEN, Denmark, May 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2026.
Denmark's Bavarian Nordic raises 2026 forecast
Denmark's Bavarian Nordic on Monday raised its revenue guidance for 2026 to 5.5 billion - 5.7 billion Danish crowns ($866.93 million-$898.46 million).
Bavarian Nordic – Completion of Share Buy-Back Program
COPENHAGEN, Denmark, May 11, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on March 12, 2026, has now been completed, reaching an ...
Resolutions of the Annual General Meeting 2026 of Bavarian Nordic A/S
COPENHAGEN, Denmark, April 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results
Bavarian Nordic Receives Swissmedic Approval for Chikungunya Vaccine
COPENHAGEN, Denmark, April 16, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Swiss Agency for Therapeutic Products, Swissmedic, has approved VIMKUNYA® (recombinant, adsorbed) for act...
Bavarian Nordic A/S – Notice Convening Annual General Meeting
COPENHAGEN, Denmark, 24 March 2026 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on
Mpox Is on the Rise. 3 Vaccine Stocks Worth a Second Look.
The first severe case of the virus has been detected in New York.
Bavarian Nordic Earnings Call Transcript: Q4 2025
Revenue reached DKK 6.2 billion in 2025, with strong growth in travel health and public preparedness, and a 28% EBITDA margin. 2026 guidance anticipates DKK 5–5.2 billion revenue and 25% EBITDA margin, with continued expansion in travel health and new agreements for chikungunya vaccine.
Bavarian Nordic Annual report: Q4 2025
Bavarian Nordic has published its Q4 2025 annual report on March 12, 2026.